These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27295707)

  • 1. [Insulinization in type 2 diabetes mellitus. Intensification options].
    Fuente GV; Sinay I; Costa Gil JE; Puchulu F; Dieuzeide G; Rodríguez M; Faingold MC; Litwak LE
    Medicina (B Aires); 2016; 76(3):173-9. PubMed ID: 27295707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Premixed insulin treatment for type 2 diabetes: analogue or human?
    Garber AJ; Ligthelm R; Christiansen JS; Liebl A
    Diabetes Obes Metab; 2007 Sep; 9(5):630-9. PubMed ID: 17697056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of insulin development: focus on key parameters.
    Tibaldi JM
    Adv Ther; 2012 Jul; 29(7):590-619. PubMed ID: 22843207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.
    Baron HL
    J Fam Pract; 2017 Oct; 66(10 Suppl):S17-S28. PubMed ID: 28991933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Insulins, Biosimilars, and Insulin Therapy.
    Danne T; Heinemann L; Bolinder J
    Diabetes Technol Ther; 2017 Feb; 19(S1):S42-S58. PubMed ID: 28192016
    [No Abstract]   [Full Text] [Related]  

  • 6. Insulin degludec. Uncertainty over cardiovascular harms.
    Prescrire Int; 2014 Jun; 23(150):149. PubMed ID: 25121146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iatrogenic hypoglycemia in patients with type 2 diabetes: comparison of insulin analog premixes and human insulin premixes.
    Martorella AJ
    Postgrad Med; 2011 Jul; 123(4):7-16. PubMed ID: 21680984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel and Emerging Insulin Preparations for Type 2 Diabetes.
    Cheung KK; Alexander P
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S160-6. PubMed ID: 26653255
    [No Abstract]   [Full Text] [Related]  

  • 9. Insulin degludec--the impact of a new basal insulin on care in type 2 diabetes.
    Khunti K; Cos X; Rutten G
    Prim Care Diabetes; 2014 Jul; 8(2):119-25. PubMed ID: 24207030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin.
    Shaefer CF; Anderson J
    Postgrad Med; 2016 Jan; 128(1):137-44. PubMed ID: 26548422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
    Vedtofte L; Knop FK; Vilsbøll T
    Expert Rev Clin Pharmacol; 2015 May; 8(3):273-82. PubMed ID: 25816888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.
    Vinik A
    Clin Ther; 2007; 29 Spec No():1236-53. PubMed ID: 18046925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin.
    Frias PF; Frias JP
    Curr Diab Rep; 2017 Aug; 17(10):91. PubMed ID: 28822051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.
    Blumer I; Pettus JH; Santos Cavaiola T
    Postgrad Med; 2018 May; 130(4):375-380. PubMed ID: 29521173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A short-acting GLP-1 analog or prandial insulin to supplement basal insulin?--Moving toward personalized management of type 2 diabetes mellitus.
    Hirsch IB; Schneider D; King A; Polonsky WH; Reid TS; Shubrook J; Verderese CA; Wallace J; Riddle MC
    Postgrad Med; 2014 May; 126(3):135-44. PubMed ID: 24918799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for insulin therapy in type 2 diabetes.
    Edelman SV; Morello CM
    South Med J; 2005 Mar; 98(3):363-71. PubMed ID: 15813164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy for hyperglycemia in pregnancy - The new insulins.
    Toledano Y; Hadar E; Hod M
    Diabetes Res Clin Pract; 2018 Nov; 145():59-66. PubMed ID: 29730391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in Type 2 Diabetes: Focus on Basal Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy.
    Shubrook JH
    J Fam Pract; 2018 Aug; 67(8 suppl):S49-S54. PubMed ID: 30137054
    [No Abstract]   [Full Text] [Related]  

  • 20. Higher concentration insulins: an overview of clinical considerations.
    Reid TS; Schafer F; Brusko C
    Postgrad Med; 2017 Jun; 129(5):554-562. PubMed ID: 28475455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.